Legend Biotech’s LB-2501 is showing early efficacy with a safety profile that is enabling investigators to frame a future outpatient CAR T approach. At EHA2026, Lei Fan of First Affiliated Hospital of Nanjing Medical University presented first-in-human data in relapsed/refractory B-cell non-Hodgkin lymphoma for LB-2501, a CD19/CD20 dual-targeting, off-the-shelf CAR T. Twelve participants across two dose levels received single infusions. At the higher dose, all six patients responded with five complete responses (CR) and one partial response (PR), including instances where responses deepened over time. Fan reported no neurotoxicity to date and the highest adverse-event grade observed so far was grade two. Legend CEO Ying Huang characterized the low observed toxicity as “a pleasant surprise,” comparing expectations to historical rates in autologous CAR T where grade 3 or higher adverse events have been reported in roughly 10% of patients.